Results 31 to 40 of about 2,753,748 (240)

Redefining Healthcare Infrastructure: Moving Toward Integrated Solutions [PDF]

open access: yes, 2010
Currently in the United Kingdom there is a trend to broaden the scope of service provision in the healthcare sector. Not only are new healthcare-related services being provided to the community, but also there is increasing concern for providing ...
Formoso, Carlos Torres   +5 more
core   +3 more sources

IgG4-Related Sclerosing Cholangitis in Europe

open access: yes, 2018
IgG4-Related sclerosing cholangitis in ...
Giulia De Marchi   +7 more
core   +1 more source

Bilateral lacrimal system involvement by sclerosing extramedullary hematopoietic tumor

open access: yes, 2019
A 60-year-old man with myelofibrosis and extramedullary hematopoiesis was referred for evaluation of “swollen lacrimal glands.” Examination disclosed bilateral firm, immobile, nontender masses in the lacrimal sac fossa with no associated signs of ...
Bowman, Adam M.   +2 more
core   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

open access: yesFEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg   +14 more
wiley   +1 more source

Geode-Conversion

open access: yes, 2023
Conversion module for Geode-solutions OpenGeode ...
Geode-solutions
core   +2 more sources

Association Between Motor Pathway Damage and Motor Deficit in Upper and Lower Limb in People With MS

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Corticospinal tract damage is common in people with MS, but the degree of clinical symptoms varies. We hypothesize that corticospinal tract lesions are more extensive and severe in people with MS with motor impairments in both upper and lower limbs.
Mathilde Liffran   +13 more
wiley   +1 more source

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree   +9 more
wiley   +1 more source

Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether discontinuing anti‐CD20 therapy in people with relapsing‐onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy.
Alexia Moukhine   +40 more
wiley   +1 more source

Increased Risk of Intrahepatic Cholestasis of Pregnancy in Women With Systemic Lupus Erythematosus Exposed to Azathioprine

open access: yesArthritis &Rheumatology, EarlyView.
Objective To evaluate the risk of intrahepatic cholestasis of pregnancy (ICP) in azathioprine (AZA)–exposed versus unexposed systemic lupus erythematosus (SLE) pregnancies within the multicenter prospective Lupus in Pregnancy (LEGACY) cohort. Methods LEGACY is conducted at Systemic Lupus International Collaborating Clinics in Canada, South Korea, Peru,
Reem Farhat   +14 more
wiley   +1 more source

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

open access: yesBiomolecules
Many drug and therapeutic modalities have emerged over the past few years. However, successful commercialization is dependent on their safety and efficacy evaluations.
Haoyu Fang   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy